Business context and reporting period
The filing is for Prestige Brands Holdings, Inc. (the issuer named in the filing), covering the fiscal third quarter and nine months ended December 31, 2014; its fiscal year ends March 31. The company markets OTC healthcare and household cleaning products. Growth included the September 2014 acquisition of Insight Pharmaceuticals for $753.2 million and the April 2014 acquisition of the Hydralyte brand for $78.0 million. The filing text does not explain the difference between this issuer name and the company name in the request metadata.
Financial performance and position
- Quarter revenue: $197.6 million, up 36.4% year over year. North American OTC Healthcare revenue rose 37.2%, driven principally by Insight; International OTC Healthcare revenue more than doubled, partly from Hydralyte.
- Quarter earnings: Gross profit was $111.7 million and operating income was $57.0 million, versus $80.5 million and $40.5 million, respectively. Net income was $21.3 million ($0.40 diluted EPS), versus $3.1 million ($0.06). Gross, operating, and net margins were approximately 56.5%, 28.8%, and 10.8%, respectively.
- Nine-month results: Revenue was $524.6 million, up 15.5%; operating income was $146.3 million, versus $143.7 million. Net income declined to $54.5 million from $56.6 million ($1.04 diluted EPS versus $1.08). Gross margin was 56.5%; operating and net margins were approximately 27.9% and 10.4%. Higher acquisition-related costs and taxes weighed on earnings.
- Cash flow: Nine-month operating cash flow was $104.1 million, up from $80.9 million. Investing used $802.9 million, mainly for Insight and Hydralyte acquisitions; financing provided $693.1 million. Cash declined $6.4 million to $22.0 million. Capital expenditures were $3.7 million.
- Debt and liquidity: Debt principal was $1.644 billion at December 31, up from $937.5 million at March 31; debt net of the $22.0 million cash balance was approximately $1.622 billion. Current assets were $200.8 million and current liabilities $91.0 million (current ratio approximately 2.2). The company reported $68.9 million of available ABL borrowing capacity and compliance with debt covenants.
Material changes versus prior comparable periods
- Quarter revenue growth largely reflected Insight, which contributed $43.4 million of quarterly revenue; acquired operations contributed $56.1 million for the nine-month period. Hydralyte also contributed to international growth.
- Quarter gross margin improved from 55.5% to 56.5%, while nine-month gross margin was unchanged at 56.5%. Household Cleaning margins weakened: nine-month segment gross margin fell from 27.1% to 24.0%, reflecting product and channel mix.
- Quarter interest expense increased to $24.6 million from $21.3 million as average debt rose; the reported average borrowing cost fell to 5.8% from 8.5% following refinancing. Nine-month interest expense rose to $57.5 million from $53.6 million.
- The nine-month effective tax rate increased to 39.5% from 24.6%, partly reflecting acquisition-related nondeductible items and the prior-year $9.1 million tax benefit. Foreign currency translation reduced nine-month comprehensive income by $16.9 million.
Outlook, risks, contingencies, and unusual items
- Management estimated an effective tax rate of approximately 35.8% for the remaining fiscal 2015 quarter, excluding acquisitions and discrete items. The filing provides no broader revenue or earnings guidance.
- PediaCare faced steeper-than-expected revenue and market-share declines amid competition, new products, and lost distribution. An interim impairment test found no impairment at December 31, 2014, but management warned continued declines, higher promotional costs, or a strategic change could lead to a future charge.
- Women’s Health supply constraints caused temporary out-of-stocks. The company was adding an alternative manufacturer and sourcing a replacement supplier for an ingredient whose current supplier planned to cease production in late calendar 2015; unresolved issues could reduce sales.
- Management anticipated higher product costs in the next fiscal year from a manufacturer price increase; inability to offset costs through pricing could pressure margins. Walmart represented 16.5% of quarterly and 17.4% of nine-month gross sales; it and Walgreens together accounted for 33.6% of receivables at quarter-end.
- Debt, variable interest rates, covenant and cross-default provisions, third-party manufacturing and distribution reliance, and the large share of assets represented by goodwill and intangibles are material risks. A one-percentage-point increase in variable rates was estimated to increase pretax expense by $2.6 million for the quarter and $4.8 million for nine months.
- Unusual items included a $1.1 million lease-termination charge, $12.6 million of nine-month acquisition costs, and a $1.1 million reported gain on an asset sale. The Comet rights transaction generated $10.0 million of proceeds and a $1.3 million gain; the licensee was to continue quarterly payments of approximately $1.0 million through at least June 30, 2016.
- The company stated routine legal matters were not expected to materially affect results; the filing gives no clear quantified estimate for potential losses. Disclosure controls were assessed as effective, with no material quarter changes in internal control over financial reporting.
Key facts investors should verify
- How much of reported growth and pro forma earnings is attributable to Insight and Hydralyte, and how their integration and performance develop.
- Whether PediaCare sales stabilize and whether the stated impairment-test assumptions remain supportable.
- Whether Women’s Health supply issues are resolved, including the ingredient supplier transition, and whether announced cost increases can be offset.
- Debt-service capacity, covenant headroom, variable-rate exposure, and the company’s ability to reduce leverage after acquisition financing.
- Cash conversion and working-capital trends, especially inventory, accounts payable, and customer concentration.